Remove Clinical Trials Remove Life Science Remove Marketing
article thumbnail

MASH Clinical Trials: New Approaches and Methodologies

XTalks

The surge in MASH cases stresses the need for early diagnosis, timely intervention and precise, reliable methodologies in clinical trials to evaluate new therapies effectively. Read on to gain insights from Medpace experts about advancements in imaging, histology and innovative techniques for MASH clinical trials.

article thumbnail

Cloudbyz Recognized in Everest Group’s 2024 PEAK Matrix® for Life Sciences CTMS Solution

Cloudbyz

This prestigious acknowledgment places Cloudbyz among the top-performing companies globally, known for delivering scalable and intuitive CTMS solutions that empower clinical research teams. Our mission is to enable faster, more efficient trials, ultimately supporting the delivery of life-saving therapies.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Xtalks Life Science Podcast: Celebrating 200 Episodes of Industry Innovation

XTalks

This week, were celebrating a significant milestone: the release of our 200th episode of the Xtalks Life Science Podcast ! We’re excited to continue our journey by bringing you more in-depth conversations with industry leaders, highlighting the innovations and trends that shape the future of life sciences.

article thumbnail

What factors are driving life sciences FDI in 2022?

Pharmaceutical Technology

In the life sciences sector, one country is significantly outstripping others for FDI. Data shows that almost 40% of all life sciences subsidiaries are located in the US. After all, around a third of the world’s leading life sciences corporations have their headquarters in the country. Industry clusters.

article thumbnail

Diversity Action Plans (DAPs) in Clinical Trials Are No Longer a “Nice-to-Have” — Are You Ready?

XTalks

In clinical research, diversity is more than a prerequisite for a successful drug — it’s a critical component that enhances the validity and applicability of clinical trial outcomes. Diversity Action Plans have now moved from being a “nice-to-have” to a “must-have” in clinical trial designs.

article thumbnail

GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics

Pharmaceutical Technology

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. On completion of the first-in-patient clinical trial by Wave, GSK will be in charge of the development and marketing works.

article thumbnail

How Private Clinical Trial Networks Can Fix What the NHS Can’t

Velocity Clinical Research

Clinical trials have been steadily leaving the UK for years. of patients recruited to global trials were from the UK. Thats not to say we dont still have some clout (the UK ranks fourth globally for Phase II trials ), but the trending outflow needs to be addressed. In 2021, just 2.2%